Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target by Thomas Reinheckel et al.
MINI REVIEW ARTICLE
published: 11 July 2012
doi: 10.3389/fphar.2012.00133
Differential impact of cysteine cathepsins on genetic
mouse models of de novo carcinogenesis: cathepsin B as
emerging therapeutic target
Thomas Reinheckel 1,2*, Christoph Peters1,2, Achim Krüger 3, BorisTurk 4,5,6,7 and OlgaVasiljeva4,8
1 Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2 Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany
3 Klinikum Rechts der Isar der Technischen Universität München, Institut für Experimentelle Onkologie undTherapieforschung, München, Germany
4 Department of Biochemistry and Molecular and Structural Biology, Jozef-Stefan-Institute, Ljubljana, Slovenia
5 Faculty of Chemistry, University of Ljubljana, Ljubljana, Slovenia
6 Center of Excellence CIPKEBIP, Ljubljana, Slovenia
7 Center of Excellence Nanosciences and Nanotechnology, Ljubljana, Slovenia
8 CytomXTherapeutics Inc., South San Francisco, CA, USA
Edited by:
Agnès Noël, University of Liege,
Belgium
Reviewed by:
Olivier Micheau, INSERM, France
Hervé Emonard, CNRS, France
*Correspondence:
Thomas Reinheckel , Institute of
Molecular Medicine and Cell
Research, Albert-Ludwigs-University
Freiburg, Stefan-Meier-Strasse 17,
D-79104 Freiburg, Germany.
e-mail: thomas.reinheckel@
uniklinik-freiburg.de
Lysosomal cysteine cathepsins belong to a family of 11 human proteolytic enzymes. Some
of them correlate with progression in a variety of cancers and therefore are considered
as potential therapeutic targets. Until recently, the contribution of individual cathepsins
to tumorigenesis and tumor progression remained unknown. By crossing various types
of mouse cancer models with mice where specific cathepsins have been ablated, we
contributed to this gap of knowledge and will summarize the results in this report. The
employed models are the Rip1-Tag2 model for pancreatic neuroendocrine tumors, the
K14-HPV16 model for squamous skin and cervical cancers, and the MMTV-PyMT model for
metastasizing breast cancer, the KPC model for pancreatic ductal adenocarcinoma, and the
APCmin mice developing early stages of intestinal neoplasia. All models harbor mutations
in relevant tumor suppressors and/or cell-type specific expression of potent oncogenes,
which initiate de novo carcinogenesis in the targeted tissues. In all these models deletion
of cathepsin B led to suppression of the aggressiveness of the respective cancer pheno-
type. Cathepsin B is networking with other proteases as it was shown for cathepsin X/Z.
In contrast, deletion of cathepsin L was beneficial in the RiP1-Tag2 model, but enhanced
tumorigenesis in the APCmin, and the K14-HPV16 mice. A logical consequence of these
results would be to further pursue selective inhibition of cathepsin B. Moreover, it became
clear that cathepsins B and S derived from cells of the tumor microenvironment support
cancer growth. Strikingly, delivery of broad spectrum cysteine cathepsin inhibitors in the
tumor microenvironment disrupts the permissive ecosystem of the cancer and results in
impaired growth or even in regression of the tumor. In addition, combination of cysteine
cathepsin inhibition and standard chemotherapy improves the therapeutic response of the
latter. Taken together, the next preclinical challenges for developing cathepsin inhibition as
cancer therapy might be the improvement of inhibitor selectivity and targeted delivery to
the tumor microenvironment and investigation of the biological context of the individual
factors within the complex proteolytic network.
Keywords: cancer, cathepsin, metastasis, microenvironment, mouse model, preclinical model, protease, protease
inhibitor
INTRODUCTION
Cysteine cathepsins are papain-like peptidases of which cathep-
sin B, C, F, H, L, K, O, S, V, W, X/Z have been identified in the
human genome and are well defined in molecular, biochemi-
cal, and structural terms (for review, Turk et al., 2001, 2012b).
Cysteine cathepsins are mainly localized in the acidic cellular com-
partments, and are involved in numerous cell biological processes
executed by the endosomal/lysosomal compartment (for review,
Muller et al., 2012). A major task for the cathepsins is their involve-
ment in the MHC class II antigen presentation pathway as well as
in the cross-presentation of antigens to MHC class complexes (for
review, Watts, 2012). However, cathepsins were also shown to be
able to escape the acidic vesicles and mediate cell death-processes
and also execute specific functions in the nucleus (for review, Turk
and Turk, 2009; Reiser et al., 2010; Repnik et al., 2012). In human
cancers, cysteine cathepsins are frequently overexpressed and are
even secreted due to gene amplification, transcriptional activa-
tion, alternative splicing, or further posttranslational processes
(for review, Mohamed and Sloane, 2006). Increased levels of cys-
teine cathepsins, among which cathepsins B and L received most
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attention, are often – but not always – correlated to a poor survival
of the cancer patients (for review, Jedeszko and Sloane, 2004). Such
correlations have been established for many solid tumor entities,
i.e., for cancers of the adrenal, bladder, breast, cervix, colon, kid-
ney, lung, ovary, pancreas, prostate, testis, and the thyroid grand
(Pietras et al., 1979; Chauhan et al., 1991; Harbeck et al., 2000,
2001; Niedergethmann et al., 2004; Troy et al., 2004; Werle et al.,
2004; Tedelind et al., 2010; Nouh et al., 2011). In general, the tumor
and metastasis-promoting effect of secreted cysteine cathepsins
is thought to be caused by their ability to degrade extracellular
matrix molecules, which in turn enables cancer cells to invade
into the surrounding tissue and to metastasize (Rothberg et al.,
2012). This simplistic model is not the whole story as in some
instances cysteine cathepsins can even promote tumor cell apop-
tosis, which would be beneficial for the patient (Vasiljeva and Turk,
2008). In addition there is evidence that proteases promote tumor
growth by processing growth factors, cytokines, and chemokines
or increasing their bioavailability by releasing them from the extra-
cellular matrix (Van Damme et al., 2004; Green and Lund, 2005;
Joyce and Pollard, 2009) and are therefore functionally embedded
in the complex proteolytic and cellular network (Lopez-Otin and
Hunter, 2010; Mason and Joyce, 2011; Turk et al., 2012a), which
renders interference with proteases more difficult (Lopez-Otin and
Overall, 2002; Noel et al., 2008; Kruger et al., 2010). The proteases
contributing to these processes and especially the relative contri-
bution of individual cysteine cathepsins are still subject to intense
investigation.
GENETIC MOUSE MODELS OF HUMAN CANCERS
Over the past decade, considerable effort was put into studying
the pathophysiological roles of individual cathepsins in complex
murine models of cancer. In the first instance, these were models
in which human or mouse cancer cells were injected into immun-
odeficient or syngenic recipient mice, respectively. The status of
cathepsin expression in the tumor cells or on the recipient site
has been modulated by RNA interference, knock-out technology,
or overexpression (Berchem et al., 2002; Gondi et al., 2004; Lakka
et al., 2004; Li et al., 2005; Alvarez-Diaz et al., 2009; Burden et al.,
2009; Ward et al., 2010; Malla et al., 2011; Withana et al., 2012).
In brief, these models provided solid evidence for amelioration
of malignant cell behavior by inhibition of one or even more
proteases in established cancer cell lines.
The focus of this review are studies, in which cathepsin knock-
out or transgenic mice with overexpression of cathepsins have been
crossed with transgenic mouse models of de novo carcinogenesis,
giving the advantage of a natural co-evolution of the growing
tumor and its microenvironment. These models are the sem-
inal Rip1-Tag2 model for pancreatic neuroendocrine neoplasia
(Hanahan, 1985; Folkman et al., 1989), the K14-HPV16 model for
squamous skin and cervical cancers (Arbeit et al., 1994; Coussens
et al., 1996), and the MMTV-PyMT model for metastasizing breast
cancer (Guy et al., 1992). All three cancer models have in com-
mon, that cell-type specific promoters induce strong expression of
potent viral oncogenes initiating malignant transformation and
stepwise tumor progression through the distinct stages of cancer
from premalignant lesions to invasive and metastasizing carci-
nomas. Hence, these models allow the assessment of the various
cell biological aspects of carcinogenesis such as proliferation, cell
death, angiogenesis, invasion, and metastasis. More recent mouse
models harbor mutations critically relevant for specific types of
human cancers. Mice that express a truncated Adenomatous Poly-
posis Coli gene product (APCmin and APC∆468) have been used to
study the role of cathepsins in early stages of intestinal neoplasia
(Moser et al., 1990; Boudreau et al., 2007; Gounaris et al., 2008).
The KPC mouse model, expressing mutations in the endogenous
KRAS and p53 genes in the exocrine pancreas, is a faithful model
of metastasizing pancreatic adenocarcinoma (Hingorani et al.,
2003, 2005; Olive et al., 2004), which has been crossed to cathep-
sin B deficient mice (Gopinathan et al., 2012). Here we present
key observations learned from investigating cathepsin-deficient
mice crossed with the above-mentioned cancer mouse models and
discuss cathepsin-directed therapy studies in these models.
CATHEPSINS IN CANCER GROWTH AND METASTASIS
Accumulating clinical and experimental data indicate that cathep-
sin B is a cancer-promoting protease (Poole et al., 1978; Sloane
et al., 1981, 1986; Nouh et al., 2011). This concept was further sup-
ported in the Rip1-Tag2 as well as in MMTV-PyMT mice, as defi-
ciency for cathepsin B resulted in slower cancer progression and
reduced invasion (Gocheva et al., 2006; Vasiljeva et al., 2006, 2008)
in both cancer models. Interestingly, the embedding of cathepsin B
in the proteolytic network was documented, as a redistribution of
cathepsin X/Z to the surface of cathepsin B deficient PyMT cancer
cells has been detected (Vasiljeva et al., 2006). Hence, cathepsin Z
was suspected to compensate for the loss of cathepsin B, a view
supported by the fact that cathepsin B and cathepsin Z are the
only enzymes with carboxypeptidase activity among the cysteine
cathepsins (Klemencic et al., 2000). Indeed, analysis of cathepsin
B/Z double-deficient mice in the context of the MMTV-PyMT
breast cancer model revealed a strongly reduced tumor and lung
metastatic burden, while a single cathepsin Z deficiency had no
clear effect on the overall tumor phenotype (Sevenich et al., 2010).
In order to model the situation of human cancers, which often
show high cathepsin B expression, transgenic mice overexpressing
human cathepsin B were crossed with MMTV-PyMT mice (Sev-
enich et al., 2011). These mice showed significantly higher tumor
burden and increased lung metastasis, which further supports a
tumor-promoting role of high cathepsin B levels. In accordance,
cathepsin B deficiency in APCmin mice reduced formation of
intestinal neoplasia (Gounaris et al., 2008). Taken together, inves-
tigation of cathepsin B deficiency and cathepsin B overexpression
in four unrelated genetic mouse models of de novo tumorigen-
esis showed consistently that cathepsin B is a tumor-promoting
protease and, therefore, a potential therapeutic target.
Single deficiencies for cathepsins B, L, S, and H perturbed the
development of Rip1-Tag2 pancreatic islet cancers, while deletion
of cathepsin C did not affect tumor progression in this model
(Gocheva et al., 2006, 2010a; Wang et al., 2006). Cathepsin L-
ablated mice showed increased carcinogenesis and frequency of
lymph node metastasis in K14-HPV16 skin cancer mice (Den-
nemarker et al., 2010). Interestingly, crossing of furless mice,
which harbor a spontaneous active site mutation of cathepsin
L, with APCmin mice increased the multiplicity of premalignant
intestinal polyps significantly (Boudreau et al., 2007). Hence, the
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contradictory result of cathepsin L ablation in the Rip1-Tag2 as
compared to the APCmin and K14-HPV16 models is an impres-
sive example for the context-dependent consequences of a gene
knock-out (Kruger, 2009). The reason for context-specific effects
of individual cathepsins in tumors might well be the fact that
these proteases play contrasting roles in carcinogenesis by acting
as positive mediators of invasion (pro-tumor), as positive or neg-
ative regulators of proliferation (pro- or anti-tumor effect), and,
in addition, may affect cell death (Goulet et al., 2004; Vasiljeva and
Turk, 2008; Vasiljeva et al., 2008; Turk and Turk, 2009). The relative
importance of these tumor biological processes in a given cancer
entity will determine the positive or negative effect of a genetic or
pharmacologic modulation of cathepsin activity in the context of
an individual malignancy.
CATHEPSINS IN TUMOR-ASSOCIATED INFLAMMATION AND
ANGIOGENESIS
The active roles of the tumor microenvironment in carcinogen-
esis and tumor progression have attracted considerable attention
during the past decade. It emerged that tumor-promoting inflam-
mation and induction of angiogenesis are hallmark characteristics
of activated tumor stroma (for review, Hanahan and Weinberg,
2011). The genetic cancer mouse models discussed here have also
been instrumental to define the role of cathepsins and endogenous
cathepsin inhibitors in the tumor microenvironment. Early studies
of intravenous injection of cancer cells isolated from MMTV-
PyMT mice into congenic cathepsin B deficient mice revealed
a decreased number and size of the resulting lung colonies as
compared to wild-type recipient mice (Vasiljeva et al., 2006).
Macrophages closely associated with these experimental lung
metastases show elevated expression of cathepsin B, suggesting
that cathepsin B expressed by metastasis-associated macrophages
has a pro-metastatic effect (Vasiljeva et al., 2006). The tumor-
promoting role of cathepsins in tumor-associated immune cells
has been elegantly proven by transfer of cathepsin-deficient bone
marrow into the Rip1-Tag2 model of pancreatic neuroendocrine
neoplasia (Gocheva et al., 2010b). The experiment revealed that
cathepsins B and S in innate immune cells promote indeed cancer
progression while cathepsins C and L did not induce this effect
(Gocheva et al., 2010b). Transfer of cathepsin L-deficient bone
marrow into the K14-HPV16 mouse model of skin cancer did
also not affect cancer progression (Dennemarker et al., 2010).
However, in both cancer models tumor progression is signifi-
cantly altered in cathepsin L knock-out mice receiving wild-type
bone marrow, suggesting a role for tumor cell-derived cathepsin
L or cathepsin L expressed by non-myeloid cells of the tumor
stroma. The importance of cathepsins in the tumor microenvi-
ronment is further supported by the finding, that genetic ablation
of the extracellular cysteine cathepsin inhibitor cystatin C facili-
tates the development of premalignant dysplasia in the epidermis
of K14-HPV16 mice (Yu et al., 2010). Tumor-associated inflam-
mation is interconnected with angiogenesis induction within the
tumor. Tumorigenesis in Rip1-Tag2 mice is highly dependent
on massive induction of blood vessel formation – the so called
“angiogenic switch.” Ablation of cathepsins B, L, S, and H, but
not of cathepsin C, resulted in impaired vascularization of the
pancreatic tumors (Gocheva et al., 2006, 2010a; Wang et al.,
2006). Evidence for a functional role of cathepsins in other, less
angiogenesis-driven, cancer models is slowly emerging. Overex-
pression of human cathepsin B in MMTV-PyMT mice resulted
in increased vascular density within the breast cancers (Sevenich
et al., 2011) and anti-angiogenic efficacy of an antibody target-
ing cathepsin S was shown in xenograft models (Ward et al.,
2010).
CATHEPSINS AS TARGETS FOR CANCER THERAPY
Overexpression and extracellular re-dislocation of cysteine cathep-
sins have been associated with multiple stages of tumorigenesis
and tumor progression (Vasiljeva et al., 2007). Thus, inhibi-
tion of cysteine cathepsins could be a potent strategy for treat-
ing cancer. The first study on the use of the broad-spectrum
small molecule cysteine cathepsin inhibitor, JPM-OEt, in the
Rip1-Tag2 pancreatic islet cells cancer mouse model demon-
strated significant anti-tumor efficacy in three distinctive trial
designs: prevention, intervention, and regression (Joyce et al.,
2004), that target different stages in tumorigenesis (Bergers et al.,
1999). Furthermore, combination of cathepsin inhibition with
two distinct regimens of chemotherapy administration (MTD or
chemo-switch) was shown to lead to a more pronounced tumor
regression, decreased tumor invasiveness, and increased survival
in the Rip1-Tag2 model (Bell-McGuinn et al., 2007). However,
there might be some limitations for the use of small synthetic
probes in the clinic, primarily because of their pharmacokinetic
properties, such as relatively short circulation half-life and poor
bioavailability, due to the rapid conversion of the injected cell
permeable ethyl esters, e.g., JPM-OEt, to its corresponding acid
in the serum (Sadaghiani et al., 2007). The latter, most prob-
ably appeared to be the reason for the failure of the JPM-OEt
inhibitor of cysteine cathepsins in the treatment study with the
MMTV-PyMT transgenic mouse mammary cancer model per-
formed in two trials on early and advanced cancers (Schurigt
et al., 2008). Notably, orthotropic injection of murine 4T1.2 mam-
mary cancer cells into the mammary gland fat pad and subse-
quent systemic administration of the highly selective cathepsin B
inhibitor CA-074 reduced bone metastasis, while JPM-OET did
not (Withana et al., 2012). Interestingly, this anti-metastatic effect
was not found for application of the widely used broad spectrum
inhibitor JPM-OET, highlighting the need for selective inhibition
of cathepsin B.
Despite the important role of tumor cell-derived cathepsins in
cancer progression, there is an increasing body of evidence con-
firming the up-regulation of cysteine cathepsins by macrophages
in the tumor microenvironment, such as macrophages (Mohamed
and Sloane, 2006). Notably, overexpression of cathepsins by
macrophages has been demonstrated to be induced by a direct
interaction with tumor cells (Vasiljeva et al., 2006), by interleukins
(Gocheva et al., 2010b), or by chemotherapy (Shree et al., 2011).
Moreover, the study of Shree et al. demonstrated a massive attrac-
tion of macrophages to tumor sites treated with chemotherapy,
with consecutive up-regulation of cathepsins by those cells. Inter-
estingly, secreted cathepsins were shown to induce tumor cell
resistance to the chemotherapy that has been supported through
co-culture and treatment experiments (Shree et al., 2011). Thus,
the approach of targeting macrophage-derived cathepsins could
be, on one hand, beneficial for the inhibition of tumor progres-
sion and invasion, and, on the other hand, could induce tumor
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cells’ sensitivity to the death signals and will increase efficacy of
standard chemotherapy drugs. In that respect, novel technologies
enabling targeting of cells of the tumor microenvironment would
be very potent in terms of the targeted delivery of cysteine cathep-
sin inhibitors to the cells of tumors primarily overexpressing
cathepsins (e.g., macrophages) and would improve pharmaco-
kinetic properties of small synthetic drugs by encapsulation in
nano-carriers (Mikhaylov and Vasiljeva, 2011). Moreover, such a
system for targeted drug delivery based on magnetic nanoparticles
and biocompatible lipid shell, forming ferri-liposomes, has been
recently developed and validated for cathepsin inhibition by the
JPM-OEt inhibitor in an orthotopically transplanted mammary
mouse cancer model (Mikhaylov et al., 2011). Notably, targeted
delivery and increased bioavailability of inhibitor through the use
of ferri-liposome nano-carriers resulted in significant cathepsin
inhibition in distant organs and led to significant reduction of
mammary tumor burden volume that have been confirmed by the
alterations in tumor marker expression, as Ki67 and E-cadherin
(Mikhaylov et al., 2011).
Taken together, the accumulated evidence in the literature
strongly supports the concept of the use of cathepsins, in par-
ticular cathepsin B, as targets for cancer therapy targets. There-
fore, inhibitors with improved pharmacokinetic properties and
improved selectivity, possibly combined with appropriate delivery
systems, and their use in combination with established chemother-
apeutic treatment strategies, will have the potential to become
valuable therapeutics for the treatment of metastatic malignant
disease in the clinic.
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